Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344640 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT03344640 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT03344640, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
Interventions
- OTHER Placebo
- DRUG secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2019-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344640
The ClinicalTrials.gov registry entry for NCT03344640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03344640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344640 about?
NCT03344640 is a clinical study titled "Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy". This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
What is the current status of trial NCT03344640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2017-12-15. Estimated completion is 2019-10-17.
What interventions are being tested in trial NCT03344640?
The interventions under investigation include: Placebo (OTHER), secukinumab (DRUG).
Who is sponsoring clinical trial NCT03344640?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.